Why the study?
Does a low-dose maintenance schedule of doxorubicin maintain remission without toxicity in children with metastatic solid tumors?
Does a low-dose maintenance schedule of doxorubicin maintain remission without toxicity in children with metastatic solid tumors?
Low-dose maintenance doxorubicin may maintain remission in pediatric solid tumors without significant toxicity, including cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports hypothesis of low-dose doxorubicin maintenance in pediatric solid tumors; hypothesis-generating and should not change practice.
A low-dose maintenance schedule of Adriamycin was evaluated in six children whose metastatic solid tumors regressed following toxic induction therapy with Adriamycin. Three of these children are now disease-free more than one year following discontinuation of therapy. Adriamycin can be given on a low-dose maintenance schedule free from alopecia, fever, stomatitis, myelosuppression and recognizable cardiomyopathy. Further studies of similar schedules are warranted.
No takes yet. Share an insight, caveat, or question.
Hvizdala et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: